# A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

Source: https://onco.cc/trials/nct07415031/  
OnCo record `nct07415031` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Adagrasib, Pembrolizumab, Cetuximab, Pemetrexed, Docetaxel and Oxaliplatin in advanced solid tumours, run by Mirati Therapeutics Inc., now recruiting.

## Summary

A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies is a phase 2 interventional study registered as NCT07415031 by Mirati Therapeutics Inc., with 170 participants planned, started 2026-05-06 and due to reach its primary completion in 2028-02-16. Interventions recorded: Adagrasib, Pembrolizumab, Cetuximab, Pemetrexed, Docetaxel and Irinotecan.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07415031
- Phase: 2
- Setting: Solid Tumor Study for Long Term Treatment of Cancer Patients Who Have Participated in BMS Parent Studies Investigating Adagrasib (BMS-986503)
- Sponsor: Mirati Therapeutics Inc.
- Enrolled: 170

## Sources

- ClinicalTrials.gov NCT07415031: https://clinicaltrials.gov/study/NCT07415031

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Adagrasib](https://onco.cc/drugs/adagrasib/), [Cetuximab](https://onco.cc/drugs/cetuximab/), [Docetaxel](https://onco.cc/drugs/docetaxel/), [Oxaliplatin](https://onco.cc/drugs/oxaliplatin/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Pemetrexed](https://onco.cc/drugs/pemetrexed/)
- companies: [Bristol Myers Squibb](https://onco.cc/companies/bms/)

---
JSON: https://onco.cc/api/v1/entities/nct07415031.json